Synonym
85548e; 85548 e; 85548-e; U-85548e; U 85548e; U85548e; Val-ser-gln-asn-leu-CH(OH)CH2-val-ile-val;
IUPAC/Chemical Name
((4S,5S)-5-((S)-4-amino-2-((S)-5-amino-2-((S)-2-((S)-2-amino-3-methylbutanamido)-3-hydroxypropanamido)-5-oxopentanamido)-4-oxobutanamido)-4-hydroxy-2-isopropyl-7-methyloctanoyl)-L-isoleucyl-L-valine
InChi Key
BURQLNQHSQGPEJ-SHSGPBBUSA-N
InChi Code
InChI=1S/C40H73N9O12/c1-11-22(10)33(39(59)48-32(21(8)9)40(60)61)49-34(54)23(19(4)5)15-28(51)25(14-18(2)3)45-36(56)26(16-30(42)53)46-35(55)24(12-13-29(41)52)44-37(57)27(17-50)47-38(58)31(43)20(6)7/h18-28,31-33,50-51H,11-17,43H2,1-10H3,(H2,41,52)(H2,42,53)(H,44,57)(H,45,56)(H,46,55)(H,47,58)(H,48,59)(H,49,54)(H,60,61)/t22-,23?,24-,25-,26-,27-,28-,31-,32-,33-/m0/s1
SMILES Code
CC(C)[C@@H](C(O)=O)NC([C@H]([C@@H](C)CC)NC(C(C(C)C)C[C@H](O)[C@@H](NC([C@H](CC(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CO)NC([C@H](C(C)C)N)=O)=O)=O)=O)CC(C)C)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
872.07
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Sawyer TK, Staples DJ, Liu L, Tomasselli AG, Hui JO, O'Connell K, Schostarez H, Hester JB, Moon J, Howe WJ, et al. HIV protease (HIV PR) inhibitor structure-activity-selectivity, and active site molecular modeling of high affinity Leu [CH(OH)CH2]Val modified viral and nonviral substrate analogs. Int J Pept Protein Res. 1992 Sep-Oct;40(3-4):274-81. PubMed PMID: 1478785.
2: Jaskólski M, Tomasselli AG, Sawyer TK, Staples DG, Heinrikson RL, Schneider J, Kent SB, Wlodawer A. Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry. 1991 Feb 12;30(6):1600-9. PubMed PMID: 1993177.
3: Obrzut SL, Koren AO, Mandelkern MA, Brody AL, Hoh CK, London ED. Whole-body radiation dosimetry of 2-[18F]Fluoro-A-85380 in human PET imaging studies. Nucl Med Biol. 2005 Nov;32(8):869-74. PubMed PMID: 16253812.
4: Swain AL, Gustchina A, Wlodawer A. Comparison of three inhibitor complexes of human immunodeficiency virus protease. Adv Exp Med Biol. 1991;306:433-41. PubMed PMID: 1812740.
5: Chen X, Tropsha A. Relative binding free energies of peptide inhibitors of HIV-1 protease: the influence of the active site protonation state. J Med Chem. 1995 Jan 6;38(1):42-8. PubMed PMID: 7837238.
6: Verkhivker GM, Rejto PA. A mean field model of ligand-protein interactions: implications for the structural assessment of human immunodeficiency virus type 1 protease complexes and receptor-specific binding. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):60-4. PubMed PMID: 8552675; PubMed Central PMCID: PMC40178.
